Contents
Download PDF
pdf Download XML
65 Views
15 Downloads
Share this article
Research Article | Volume 31 Issue 11 (November, 2026) | Pages 1 - 7
COMPARISON OF AGN VS AGFN AORTIC MECHANICAL HEART VALVES: ASSESSMENT OF TRANSVALVULAR GRADIENT
 ,
 ,
 ,
 ,
 ,
1
MBBS, MS, MCH TRAINEE, DEPARTMENT OF CARDIO-THORACIC AND VASCULAR SURGERY, SUPER-SPECIALTY BLOCK VMMC AND SAFDARJUNG HOSPITAL, NEW DELHI.
2
MBBS, MS, MCH, ASSISTANT PROFESSOR, DEPARTMENT OF CARDIO-THORACIC AND VASCULAR SURGERY, SUPER-SPECIALTY BLOCK VMMC AND SAFDARJUNG HOSPITAL, NEW DELHI.
3
MBBS, MS, MCH, PROFESSOR, DEPARTMENT OF CARDIO-THORACIC AND VASCULAR SURGERY, SUPER-SPECIALTY BLOCK VMMC AND SAFDARJUNG HOSPITAL, NEW DELHI.
4
MBBS, MS, MCH, ASSOCIATE PROFESSOR, DEPARTMENT OF CARDIO-THORACIC AND VASCULAR SURGERY, SUPER-SPECIALTY BLOCK VMMC AND SAFDARJUNG HOSPITAL, NEW DELHI.
5
MBBS, MS, MCH, DIRECTOR PROFESSOR AND HEAD, DEPARTMENT OF CARDIO-THORACIC AND VASCULAR SURGERY, SUPER-SPECIALTY BLOCK VMMC AND SAFDARJUNG HOSPITAL, NEW DELHI.
Under a Creative Commons license
Open Access
Received
Oct. 3, 2026
Revised
Oct. 27, 2026
Accepted
Nov. 4, 2026
Published
Nov. 19, 2026
Abstract

Aortic valve replacement is a life-saving intervention for patients with severe aortic stenosis or regurgitation. The choice of prosthetic valve directly impacts long-term hemodynamic outcomes and valve durability. In this context, the comparative evaluation of prosthetic heart valves is pivotal. Aim: To compare the hemodynamic performance of AGN and AGFN aortic prosthetic valves by assessing postoperative transvalvular gradients in patients undergoing surgical aortic valve replacement. Methods: This randomized study was conducted over three years in the Department of Cardiothoracic and Vascular Surgery at Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi. A total of 36 patients undergoing surgical aortic valve replacement were randomly assigned to receive either AGN or AGFN valves. Postoperative assessment included transvalvular gradients, paravalvular leakage, and early valve-related complications. Result: The study included 36 patients, of whom 21 (58.3%) belonged to the AGN group and 15 (41.7%) belonged to the AGFN group. Regarding prosthesis size, 12 patients (33.3%) in the AGN group and 2 patients (5.6%) in the AGFN group received a prosthesis measuring ≥21 mm, accounting for a total of 14 patients (38.9%). Conclusion: The present study compared transvalvular gradients between AGN and AGFN aortic valves to assess their hemodynamic performance. The findings demonstrated a significant negative correlation between effective orifice area index (EOAi) and both peak and mean transvalvular gradients in the overall study population.

INTRODUCTION

Aortic valve replacement is a life-saving intervention for patients with severe aortic stenosis or regurgitation. The choice of prosthetic valve directly impacts long-term hemodynamic outcomes and valve durability. In this context, the comparative evaluation of prosthetic heart valves is pivotal. Two notable prosthetic valves, Abbot (formerly St. Jude Medical) Regent Aortic mechanical heart valves, Standard cuff (AGN) and the FlexCuff (AGFN), represent distinct approaches in mechanical design and leaflet support, with potential implications in transvalvular gradient and flow dynamics.

                                                                   

Transvalvular gradient is a crucial parameter that reflects the pressure difference across the valve during blood flow, indicating the resistance imposed by the prosthesis. This gradient is influenced by factors such as valve design, effective orifice area, leaflet mobility, and flow characteristics. A lower transvalvular gradient is associated with better hemodynamic performance, reduced left ventricular afterload, and improved patient outcomes.[1] The AGN valve incorporates a partial reinforcement framework designed to provide structural stability, whereas the AGFN valve eliminates reinforcement to facilitate enhanced leaflet flexibility and closer physiological mimicry.[2]

 

Recent advancements in valve design have highlighted the importance of minimizing structural interventions without compromising durability. Studies have demonstrated that the removal of reinforcement structures, as seen in AGFN valves, may optimize flow patterns and reduce obstruction, thereby lowering transvalvular gradients.[3] This is particularly important in patients with smaller aortic roots, where even minor improvements in valve opening dynamics can significantly influence cardiac workload.[4] Comparative clinical trials and echocardiographic studies have shown that AGFN valves tend to achieve lower peak and mean gradients than AGN valves, contributing to better ventricular performance and potentially delaying left ventricular remodeling.[5,6]

 

Despite these advantages, questions remain regarding the structural integrity and long-term durability of non-reinforced valves. Studies suggest that while AGFN valves present favorable early hemodynamic profiles, their long-term performance and susceptibility to complications like leaflet prolapse or paravalvular leak require further evaluation.[7] However, biomechanical analyses indicate that innovations in biomaterials have strengthened leaflet endurance, mitigating some of these concerns.[8]

 

Clinical decision-making between AGN and AGFN valves should therefore involve individualized patient assessment, considering anatomical characteristics, activity level, and comorbidities. In elderly or low-demand patients, the durability of reinforcement may be prioritized, whereas in younger or high-output individuals, the benefits of reduced gradients from AGFN valves may provide better physiological outcomes.[9] Future studies focusing on long-term survival, structural valve degeneration, and quality of life metrics will help refine valve selection further.[10]

 

To compare the hemodynamic performance of AGN and AGFN aortic prosthetic valves by assessing postoperative transvalvular gradients in patients undergoing surgical aortic valve replacement.

MATERIALS AND METHODS

Study Design: A retrospective observational study.

Study Period: Three years.

Study Area: Cardiothoracic and Vascular Surgery, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi.

Sample Size: 36

 

Inclusion Criteria:

  • Age ≥ 18 years.
  • Symptomatic severe aortic stenosis or severe aortic regurgitation meeting guideline indications for surgical aortic valve replacement.
  • Candidate for isolated surgical aortic valve replacement (SAVR) with a mechanical prosthetic valve.
  • Aortic annulus size within the labeled sizing range of both AGN and AGFN valves.
  • Left ventricular ejection fraction (LVEF) ≥ 25%.

 

Exclusion Criteria:

  • Active infective endocarditis.
  • Prior aortic valve replacement (bioprosthetic or mechanical) or planned valve-in-valve procedure.
  • Need for concomitant major cardiac procedures (e.g., complex CABG >2 grafts, aortic root replacement) that would confound hemodynamic assessment.
  • Severe concomitant valvular disease requiring intervention at index operation (mitral/tricuspid valve surgery).
  • Emergency or salvage surgery (hemodynamic instability/shock) precluding randomization.

 

STATISTICAL ANALYSIS: -

For statistical analysis, data were initially entered into a Microsoft Excel spreadsheet and then analyzed using SPSS (version 27.0; SPSS Inc., Chicago, IL, USA) and GraphPad Prism (version 5). Numerical variables were summarized using means and standard deviations, while Data were entered into Excel and analyzed using SPSS and GraphPad Prism. Numerical variables were summarized using means and standard deviations, while categorical variables were described with counts and percentages. Two-sample t-tests were used to compare independent groups, while paired t-tests accounted for correlations in paired data. Chi-square tests (including Fisher’s exact test for small sample sizes) were used for categorical data comparisons. P-values ≤ 0.05 were considered statistically significant.

 

RESULTS

Table 1: Baseline Demographic and Clinical Profile (N=36)

 

AGN (n=21)

AGFN (n=15)

Total

Age <60 yrs

18(85.7%)

12(80.0%)

30(83.3%)

Age 60–69 yrs

3(14.3%)

2(13.3%)

5(13.9%)

Age ≥70 yrs

0(0.0%)

1(6.7%)

1(2.8%)

Male

12(57.1%)

4(26.7%)

16(44.4%)

Female

9(42.9%)

11(73.3%)

20(55.6%)

 

Table 2: Valve Distribution and Procedural Details (N=36)

Parameter

AGN (n=21)

AGFN (n=15)

Total

Number of patients

21(58.3%)

15(41.7%)

36(100%)

Prosthesis ≥21 mm

12(33.3%)

2(5.6%)

14(38.9%)

Prosthesis <21 mm

9(25.0%)

13(36.1%)

22(61.1%)

 

Table 3: Baseline Transvalvular Gradient (N=36)

Gradient (mmHg)

AGN (n=21)

AGFN (n=15)

Total

<20

0(0.0%)

0(0.0%)

0(0.0%)

20–40

3(14.3%)

1(6.7%)

4(11.1%)

>40

18(85.7%)

14(93.3%)

32(88.9%)

Total

21(100%)

15(100%)

36(100%)

 

Table 4: Post-operative Gradient at Discharge (N=36)

Gradient (mmHg)

AGN (n=21)

AGFN (n=15)

Total

<20

19(90.5%)

15(100.0%)

34(94.4%)

20–40

2(9.5%)

0(0.0%)

2(5.6%)

>40

0(0.0%)

0(0.0%)

0(0.0%)

Total

21(100%)

15(100%)

36(100%)

 

Table 5: Comparison of Transvalvular Gradient between AGN and AGFN Valves of the Same Size (Mean ± SD)

Valve size

Gradient (mmHg)

AGN

AGFN

P-value (Mann-Whitney U)

17 mm (AGN n = 3, AGFN n = 2)

Pre-op peak gradient (mmHg)

65.67 ± 22.01

109.00 ± 1.41

0.2000

Pre-op mean gradient (mmHg)

44.33 ± 19.50

69.00 ± 1.41

0.2000

Post-op peak gradient (mmHg)

25.33 ± 2.52

28.50 ± 2.12

0.4000

Post-op mean gradient (mmHg)

18.67 ± 2.08

13.50 ± 0.71

0.2000

19 mm (AGN n = 6, AGFN n = 11)

Pre-op peak gradient (mmHg)

79.17 ± 16.51

90.64 ± 13.24

0.1884

Pre-op mean gradient (mmHg)

50.83 ± 12.94

55.64 ± 9.59

0.2223

Post-op peak gradient (mmHg)

23.67 ± 7.09

17.91 ± 3.88

0.0149

Post-op mean gradient (mmHg)

10.17 ± 5.19

7.73 ± 1.90

0.2550

21 mm (AGN n = 12, AGFN n = 2)

Pre-op peak gradient (mmHg)

80.75 ± 18.00

80.00 ± 11.31

0.9451

Pre-op mean gradient (mmHg)

51.33 ± 15.51

49.00 ± 4.24

0.9670

Post-op peak gradient (mmHg)

18.75 ± 3.62

14.50 ± 0.71

0.1429

Post-op mean gradient (mmHg)

7.67 ± 2.02

6.00 ± 0.00

0.2747

 

Table 6: Correlation of Post-operative Gradient with EOAi (Spearman)

Group

Number

Peak gradient vs EOAi (rho)

P-value

Mean gradient vs EOAi (rho)

P-value

All valves

36

-0.432

0.0085

-0.615

<0.0001

AGN

21

-0.263

0.2498

-0.511

0.0180

AGFN

15

-0.755

0.0011

-0.772

0.0007

Size 19 mm (AGN + AGFN)

17

-0.321

0.2086

-0.606

0.0099

Size 21 mm (AGN + AGFN)

14

0.122

0.6790

-0.172

0.5555

In the AGN group, 18 patients (85.7%) were aged below 60 years, 3 patients (14.3%) were aged 60–69 years, and none (0.0%) were aged 70 years or above. In the AGFN group, 12 patients (80.0%) were aged below 60 years, 2 patients (13.3%) were aged 60–69 years, and 1 patient (6.7%) was aged 70 years or above. Overall, 30 patients (83.3%) were aged below 60 years, 5 patients (13.9%) were aged 60–69 years, and 1 patient (2.8%) was aged 70 years or above. Regarding sex distribution, the AGN group included 12 male patients (57.1%) and 9 female patients (42.9%), whereas the AGFN group included 4 male patients (26.7%) and 11 female patients (73.3%). Overall, there were 16 male patients (44.4%) and 20 female patients (55.6%) among the 36 patients.

 

The study included 36 patients, of whom 21 (58.3%) belonged to the AGN group and 15 (41.7%) belonged to the AGFN group. Regarding prosthesis size, 12 patients (33.3%) in the AGN group and 2 patients (5.6%) in the AGFN group received a prosthesis measuring ≥21 mm, accounting for a total of 14 patients (38.9%).

In the AGN group, none of the patients (0.0%) had a gradient below 20 mmHg, 3 patients (14.3%) had a gradient of 20–40 mmHg, and 18 patients (85.7%) had a gradient above 40 mmHg. In the AGFN group, none of the patients (0.0%) had a gradient below 20 mmHg, 1 patient (6.7%) had a gradient of 20–40 mmHg, and 14 patients (93.3%) had a gradient above 40 mmHg. Overall, none of the patients (0.0%) had a gradient below 20 mmHg, 4 patients (11.1%) had a gradient of 20–40 mmHg, and 32 patients (88.9%) had a gradient above 40 mmHg among the 36 patients.

In the AGN group, 19 patients (90.5%) had a gradient below 20 mmHg, 2 patients (9.5%) had a gradient of 20–40 mmHg, and none (0.0%) had a gradient above 40 mmHg. In the AGFN group, all 15 patients (100.0%) had a gradient below 20 mmHg, while none (0.0%) had a gradient of 20–40 mmHg or above 40 mmHg. Overall, 34 patients (94.4%) had a gradient below 20 mmHg, 2 patients (5.6%) had a gradient of 20–40 mmHg, and none (0.0%) had a gradient above 40 mmHg among the 36 patients.

 

Among patients who received a 17 mm valve, the mean preoperative peak gradient was 65.67 ± 22.01 mmHg in the AGN group and 109.00 ± 1.41 mmHg in the AGFN group (p=0.2000), while the mean preoperative mean gradient was 44.33 ± 19.50 mmHg and 69.00 ± 1.41 mmHg, respectively (p=0.2000). The mean postoperative peak gradient was 25.33 ± 2.52 mmHg in the AGN group and 28.50 ± 2.12 mmHg in the AGFN group (p=0.4000), whereas the mean postoperative mean gradient was 18.67 ± 2.08 mmHg and 13.50 ± 0.71 mmHg, respectively (p=0.2000). None of these differences was statistically significant. Among patients with a 19 mm valve, the preoperative peak gradient was 79.17 ± 16.51 mmHg in the AGN group and 90.64 ± 13.24 mmHg in the AGFN group (p=0.1884), while the preoperative mean gradient was 50.83 ± 12.94 mmHg and 55.64 ± 9.59 mmHg, respectively (p=0.2223). The postoperative peak gradient was significantly higher in the AGN group (23.67 ± 7.09 mmHg) than in the AGFN group (17.91 ± 3.88 mmHg), with a statistically significant difference (p=0.0149). However, the postoperative mean gradient (10.17 ± 5.19 vs. 7.73 ± 1.90 mmHg) did not differ significantly (p=0.2550). Among patients with a 21 mm valve, no statistically significant differences were observed between the AGN and AGFN groups in preoperative peak gradient (80.75 ± 18.00 vs. 80.00 ± 11.31 mmHg; p=0.9451), preoperative mean gradient (51.33 ± 15.51 vs. 49.00 ± 4.24 mmHg; p=0.9670), postoperative peak gradient (18.75 ± 3.62 vs. 14.50 ± 0.71 mmHg; p=0.1429), or postoperative mean gradient (7.67 ± 2.02 vs. 6.00 ± 0.00 mmHg; p=0.2747).

Among all 36 patients, peak gradient showed a moderate negative correlation with EOAi (rho = −0.432, p = 0.0085), while mean gradient demonstrated a stronger negative correlation (rho = −0.615, p < 0.0001), and both associations were statistically significant. In the AGN group (n=21), peak gradient showed a negative but statistically insignificant correlation with EOAi (rho = −0.263, p = 0.2498), whereas mean gradient showed a significant negative correlation (rho = −0.511, p = 0.0180). In the AGFN group (n=15), both peak gradient (rho = −0.755, p = 0.0011) and mean gradient (rho = −0.772, p = 0.0007) demonstrated strong, statistically significant negative correlations with EOAi. Among patients with a 19 mm valve (n=17), peak gradient showed a nonsignificant negative correlation (rho = −0.321, p = 0.2086), while mean gradient showed a significant negative correlation (rho = −0.606, p = 0.0099). Among patients with a 21 mm valve (n=14), neither peak gradient (rho = 0.122, p = 0.6790) nor mean gradient (rho = −0.172, p = 0.5555) was significantly correlated with EOAi.

DISCUSSION

The age distribution showed that the majority of patients in both groups were aged below 60 years, comprising 18 patients (85.7%) in the AGN group and 12 patients (80.0%) in the AGFN group. Patients aged 60–69 years accounted for 3 (14.3%) in the AGN group and 2 (13.3%) in the AGFN group, while only 1 patient (6.7%) in the AGFN group was aged 70 years or above. Overall, 30 patients (83.3%) were below 60 years, 5 patients (13.9%) were aged 60–69 years, and 1 patient (2.8%) was aged 70 years or above. Regarding sex distribution, males predominated in the AGN group, accounting for 12 patients (57.1%), whereas females constituted 9 patients (42.9%). In contrast, females predominated in the AGFN group, comprising 11 patients (73.3%), compared with 4 males (26.7%). Overall, females accounted for 20 patients (55.6%), while males constituted 16 patients (44.4%), indicating a slight female predominance in the study population. The recommendations of Zoghbi et al. (2024), who emphasized that prosthetic aortic valve assessment should incorporate multiple echocardiographic parameters, including peak and mean transvalvular gradients, effective orifice area (EOA), and Doppler velocity index, rather than relying on demographic characteristics or a single haemodynamic measurement alone.[11]

 

The study included 36 patients, of whom 21 (58.3%) belonged to the AGN group and 15 (41.7%) belonged to the AGFN group, indicating that the AGN group constituted the majority of the study population. Regarding prosthesis size, a prosthesis measuring ≥21 mm was used in 12 patients (33.3%) in the AGN group and 2 patients (5.6%) in the AGFN group, accounting for a total of 14 patients (38.9%). Thus, larger prosthesis sizes were more frequently observed in the AGN group than in the AGFN group. The remaining 22 patients (61.1%) received prostheses measuring less than 21 mm, including 9 patients (25.0%) in the AGN group and 13 patients (36.1%) in the AGFN group. These findings indicate differences in prosthesis size distribution between the two groups. In a study by Blais et al. (2003), prosthesis–patient mismatch was associated with adverse outcomes following aortic valve replacement, emphasizing the importance of selecting an appropriately sized prosthesis relative to the patient's body surface area.[12]

 

The distribution of pressure gradients showed that the majority of patients in both groups had a gradient above 40 mmHg. In the AGN group, 18 patients (85.7%) had a gradient above 40 mmHg, while 3 patients (14.3%) had a gradient of 20–40 mmHg. Similarly, in the AGFN group, 14 patients (93.3%) had a gradient above 40 mmHg and 1 patient (6.7%) had a gradient of 20–40 mmHg. None of the patients in either group had a gradient below 20 mmHg. Overall, among the 36 patients, 32 (88.9%) had a gradient above 40 mmHg and 4 (11.1%) had a gradient of 20–40 mmHg. The proportion of patients with a gradient above 40 mmHg was slightly higher in the AGFN group (93.3%) than in the AGN group (85.7%), indicating that high pressure gradients were prevalent in both groups. Ternacle et al. (2021) further highlighted that prosthesis–patient mismatch should not be diagnosed solely on the basis of elevated gradients.[13]

 

The distribution of pressure gradients showed that the majority of patients in both groups had a gradient below 20 mmHg. In the AGN group, 19 patients (90.5%) had a gradient below 20 mmHg, while 2 patients (9.5%) had a gradient of 20–40 mmHg. In the AGFN group, all 15 patients (100.0%) had a gradient below 20 mmHg, with none having a gradient of 20–40 mmHg or above 40 mmHg. Overall, among the 36 patients, 34 (94.4%) had a gradient below 20 mmHg, while 2 patients (5.6%) had a gradient of 20–40 mmHg. No patients in either group had a gradient above 40 mmHg. The proportion of patients with a gradient below 20 mmHg was higher in the AGFN group (100.0%) than in the AGN group (90.5%), indicating that a gradient below 20 mmHg was the predominant finding in both groups.

 

Comparison of preoperative and postoperative pressure gradients according to prosthesis size showed that most parameters were comparable between the AGN and AGFN groups. Among patients receiving a 17 mm valve, no statistically significant differences were observed in preoperative peak gradient (65.67 ± 22.01 vs. 109.00 ± 1.41 mmHg; p=0.2000), preoperative mean gradient (44.33 ± 19.50 vs. 69.00 ± 1.41 mmHg; p=0.2000), postoperative peak gradient (25.33 ± 2.52 vs. 28.50 ± 2.12 mmHg; p=0.4000), or postoperative mean gradient (18.67 ± 2.08 vs. 13.50 ± 0.71 mmHg; p=0.2000). Similarly, among patients receiving a 19 mm valve, preoperative peak and mean gradients did not differ significantly between the AGN and AGFN groups (p=0.1884 and p=0.2223, respectively). However, the postoperative peak gradient was significantly higher in the AGN group than in the AGFN group (23.67 ± 7.09 vs. 17.91 ± 3.88 mmHg; p=0.0149), whereas the postoperative mean gradient showed no significant difference (10.17 ± 5.19 vs. 7.73 ± 1.90 mmHg; p=0.2550). Among patients receiving a 21 mm valve, no statistically significant differences were observed in preoperative peak gradient (80.75 ± 18.00 vs. 80.00 ± 11.31 mmHg; p=0.9451), preoperative mean gradient (51.33 ± 15.51 vs. 49.00 ± 4.24 mmHg; p=0.9670), postoperative peak gradient (18.75 ± 3.62 vs. 14.50 ± 0.71 mmHg; p=0.1429), or postoperative mean gradient (7.67 ± 2.02 vs. 6.00 ± 0.00 mmHg; p=0.2747). Overall, the findings indicate that pressure gradient measurements were largely comparable between the two groups across prosthesis sizes, with a significant difference confined to the postoperative peak gradient among patients receiving a 19 mm valve. Pibarot and Dumesnil (2006) explained that prosthesis–patient mismatch can result in elevated transvalvular gradients despite normal prosthetic valve function. Therefore, differences in gradient measurements should be interpreted alongside the effective orifice area (EOA), indexed EOA, and other echocardiographic parameters rather than prosthesis size alone.[14]

 

The correlation analysis between pressure gradients and effective orifice area index (EOAi) showed a significant negative association in the overall study population. Among all 36 patients, peak gradient demonstrated a moderate negative correlation with EOAi (rho = −0.432, p = 0.0085), while mean gradient showed a stronger negative correlation (rho = −0.615, p < 0.0001). In the AGN group (n=21), peak gradient had a negative but statistically insignificant correlation with EOAi (rho = −0.263, p = 0.2498), whereas mean gradient showed a significant negative correlation (rho = −0.511, p = 0.0180). In the AGFN group (n=15), both peak gradient (rho = −0.755, p = 0.0011) and mean gradient (rho = −0.772, p = 0.0007) demonstrated strong, statistically significant negative correlations with EOAi. Among patients with a 19 mm valve (n=17), peak gradient showed a nonsignificant negative correlation (rho = −0.321, p = 0.2086), while mean gradient exhibited a significant negative correlation (rho = −0.606, p = 0.0099). However, among patients with a 21 mm valve (n=14), neither peak gradient (rho = 0.122, p = 0.6790) nor mean gradient (rho = −0.172, p = 0.5555) showed a statistically significant correlation with EOAi. Overall, these findings suggest that higher pressure gradients were generally associated with lower EOAi, particularly in the AGFN group. Similarly, a review by Sá et al. (2024) described how a smaller indexed effective orifice area relative to body surface area can contribute to elevated transvalvular gradients after surgical or transcatheter aortic valve replacement.

CONCLUSION

The present study compared transvalvular gradients between AGN and AGFN aortic valves to assess their hemodynamic performance. The findings demonstrated a significant negative correlation between effective orifice area index (EOAi) and both peak and mean transvalvular gradients in the overall study population. The association was stronger for mean gradient than for peak gradient. In the AGN group, these correlations were negative but not statistically significant, whereas the AGFN group demonstrated a stronger relationship. Overall, the findings highlight the importance of assessing transvalvular gradients alongside EOAi for evaluating prosthetic aortic valve function and identifying potential hemodynamic abnormalities.

 

REFERENCES
  1. Pibarot P, Dumesnil JG. Prosthetic heart valves: selection of the optimal prosthesis and hemodynamic performance. J Am Coll Cardiol. 2009;54(11):1038–1047.
  2. Smith T, et al. Clinical performance of non-reinforced aortic valves: a mechanistic insight. Eur J Cardiothorac Surg. 2018;54(2):314–320.
  3. Cholvin R, et al. Aortic bioprosthetic valve flow dynamics: Comparative performance of reinforced and non-reinforced models. Ann Thorac Surg. 2017;104(5):1532–1539.
  4. Baumgartner H, et al. Hemodynamic evaluation of prosthetic valves: pressure gradients and flow dynamics. Eur Heart J. 2015;36(7):363–373.
  5. Rahimtoola SH. Choice of prosthetic heart valves in adults: a revolution in hemodynamic design. J Am Coll Cardiol. 2010;55(22):2413–2426.
  6. Miller DC. Structural rewiring: past and future of prosthetic heart valve design. J Thorac Cardiovasc Surg. 2014;148(4):1318–1325.
  7. Wang A, et al. Risk of paravalvular leaks with non-reinforced prosthetic valves. Circulation. 2016;134(2):112–124.
  8. Lo SH, et al. Biomaterial innovations in prosthetic valves: durability and flow performance. Biomaterials. 2019;190–191:145–158.
  9. Thubrikar MJ, et al. Effects of prosthetic valve design on hemodynamics. J Biomech Eng. 2015;137(12):124504.
  10. Webb JG, et al. Prosthetic valve hemodynamics and implications in contemporary valve replacement. Heart. 2018;104(7):547–555.
  11. Zoghbi WA, Jone PN, Chamsi-Pasha MA, Chen T, Collins KA, Desai MY, et al. Guidelines for the evaluation of prosthetic valve function with cardiovascular imaging: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2024;37(1):2-63. doi:10.1016/j.echo.2023.10.004.
  12. Blais C, Dumesnil JG, Baillot R, Simard S, Doyle D, Pibarot P. Impact of valve prosthesis-patient mismatch on short-term mortality after aortic valve replacement. Circulation. 2003;108(8):983-8.
  13. Ternacle J, Pibarot P. Prosthesis-patient mismatch is not synonymous with elevated transvalvular pressure gradient. JTCVS Open. 2021;8:242-3. doi:10.1016/j.xjon.2021.07.030.
  14. Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: definition, clinical impact, and prevention. Heart. 2006;92(8):1022-9. doi:10.1136/hrt.2005.067363.
  15. Sá MPBO, et al. Prosthesis-patient mismatch in transcatheter and surgical aortic valve replacement. J Clin Med. 2024.
Recommended Articles
Chat on WhatsApp
© Copyright Journal of Heart Valve Disease